The tumor profiling assay will have similar chemistry and analytics to TruSight Oncology 500 (TSO 500). The IVD test is now undergoing regulatory review and is set to be launched in both the U.S. and Europe later this year . . .
Home Information Management Bioinformatics Illumina Launching Pan-Cancer IVD Test, Cloud-Based Bioinformatics Platform
- Information Management
- Bioinformatics
- Translational Medicine
- Biomarkers
- Cancer
- Circulating Tumor Cell
- GEN Edge
- Illumina
- Molecular Diagnostics/In vitro Diagnostics
- Sequencing
- Next-Generation Sequencing
- OMICs
Illumina Launching Pan-Cancer IVD Test, Cloud-Based Bioinformatics Platform
CEO Francis deSouza says tech breakthroughs will enable the long-discussed $100 genome
Illumina has revealed plans to step up its cancer detection efforts by launching a new in vitro diagnostic (IVD) test and bolstering its oncology-focused companion diagnostic (CDx) collaborations—as well as plans to launch a new cloud-based bioinformatics data platform. [Illumina]
